Different surgical methods for FIGO stage IVB cervical cancer patients receiving chemotherapy: a population-based study
Journal of Gynecologic Oncology · 2025
DOI: 10.3802/jgo.2025.36.e42 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2025. Verfasst von Haoran Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: To assess survival differences between non-extensive surgery (NES) and extensive surgery (ES) in International Federation of Gynecology and Obstetrics (FIGO) stage IVB cervical cancer patients receiving chemotherapy from a population-based database, the Surveillance, Epidemiology and End Results. METHODS: Propensity matching was conducted to minimize heterogeneity. Survival analysis was performed by the Kaplan-Meier method, log-rank test, and Cox proportional hazards model. RESULTS: A total of 154 patients met screening criteria, among whom 84 patients (84/154) underwent NES while 70 patients (70/154) underwent ES. After matching, no survival advantage was observed in ES group compared with NES group (p=0.066; hazard ratio [HR]=1.54; 95% confidence interval [CI]=0.97-2.42). Stratified analyses suggested ES prolonged overall survival in patients with histology other than squamous cell carcinoma and adenocarcinoma (p=0.028; HR=0.36; 95% CI=0.15-0.89) and American Joint Committee on Cancer (AJCC) T stage T1 (p=0.009; HR=0.18; 95% CI=0.05-0.66). Despite no survival benefit after regional lymph node surgery (p=0.629; HR=0.88; 95% CI=0.53-1.47), subgroup analyses demonstrated that patients younger than 50 (p=0.006; HR=0.21; 95% CI=0.07-0.64), with AJCC T stage T1 (p=0.002; HR=0.09; 95% CI=0.02-0.42), T3 (p=0.001; HR=0.02; 95% CI=0.00-0.21), hematogenous metastasis (p=0.036; HR=0.27; 95% CI=0.08-0.92) and without surgery of other sites (p=0.040; HR=0.01; 95% CI=0.00-0.79) might achieve longer survival after regional lymph node surgery. CONCLUSION: In conclusion, ES or regional lymph node surgery may provide survival advantage for certain subgroup of FIGO IVB cervical cancer patients receiving chemotherapy. However, it deserves large scale prospective clinical trials to confirm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Gynecological Oncology, Minhang Branch, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Gynecological Oncology, Minhang Branch, Fudan University Shanghai Cancer Center, Shanghai, China. cheng_xi1@hotmail.com.
ORCID-Profile: Haoran Li, Jiao Wu, Qing Xu, Yixin Chen, Xi Cheng
Zitieren
APA
Li, H., Wu, J., Xu, Q., Chen, Y., & Cheng, X. (2025). Different surgical methods for FIGO stage IVB cervical cancer patients receiving chemotherapy: a population-based study. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2025.36.e42
Vancouver
Li H, Wu J, Xu Q, Chen Y, Cheng X. Different surgical methods for FIGO stage IVB cervical cancer patients receiving chemotherapy: a population-based study. Journal of Gynecologic Oncology. 2025. doi:10.3802/jgo.2025.36.e42
BibTeX
@article{Li2025,
author = {Li, Haoran and Wu, Jiao and Xu, Qing and Chen, Yixin and Cheng, Xi},
title = {Different surgical methods for FIGO stage IVB cervical cancer patients receiving chemotherapy: a population-based study},
journal = {Journal of Gynecologic Oncology},
year = {2025},
doi = {10.3802/jgo.2025.36.e42}
}
EUVIMED